Suppr超能文献

接受根治性膀胱切除术治疗的临床 T1 级 3 级尿路上皮癌患者的特征和结局:来自国际队列的结果。

Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort.

机构信息

Caritas-St. Josef Medical Centre, University of Regensburg, Regensburg, Germany.

出版信息

Eur Urol. 2010 Feb;57(2):300-9. doi: 10.1016/j.eururo.2009.09.024. Epub 2009 Sep 12.

Abstract

BACKGROUND

Management of T1 grade 3 (T1G3) urothelial carcinoma of the bladder (UCB), with its variable behaviour, represents one of the most difficult challenges for urologists and patients alike.

OBJECTIVE

To evaluate the characteristics and long-term outcome of patients with clinical T1G3 UCB treated with radical cystectomy (RC).

DESIGN, SETTING, AND PARTICIPANTS: Data from 1136 patients treated with RC for clinical T1G3 UCB without neoadjuvant chemotherapy were collected at 12 centres located in Europe, the United States, and Canada. Median age was 67 yr (range: 29-94), with a male-to-female ratio of 4:1.

MEASUREMENTS

Patients' characteristics and outcome are evaluated.

RESULTS AND LIMITATIONS

Of the 1136 patients, 33.4% had non-organ-confined stage at cystectomy, and 16.2% had lymph node (LN) metastasis; 49.7% were upstaged after RC to muscle-invasive disease, while 21.4% were downstaged to lower than T1G3. Within a median follow-up of 48 mo, 35.5% of patients died of metastatic UCB.

CONCLUSIONS

Approximately half of the patients treated with RC without neoadjuvant chemotherapy for clinical T1G3 UCB are upstaged to muscle-invasive UCB. These rates support the inadequacy of clinical decision making based on current treatment paradigms and staging tools. Therefore, identification of patients with clinical T1G3 disease at high risk of disease progression is of the utmost importance, as these patients are likely to benefit from early RC.

摘要

背景

T1 级 3 级(T1G3)膀胱癌(UCB)的治疗具有多变的特点,是泌尿科医生和患者面临的最大挑战之一。

目的

评估接受根治性膀胱切除术(RC)治疗的临床 T1G3 UCB 患者的特征和长期预后。

设计、地点和参与者:从欧洲、美国和加拿大的 12 个中心收集了 1136 名接受 RC 治疗且无新辅助化疗的临床 T1G3 UCB 患者的数据。中位年龄为 67 岁(范围:29-94 岁),男女比例为 4:1。

测量

评估患者的特征和结局。

结果和局限性

在 1136 名患者中,33.4%的患者在膀胱切除术后为非器官受限期,16.2%的患者有淋巴结(LN)转移;49.7%的患者在 RC 后升级为肌层浸润性疾病,而 21.4%的患者降级为低于 T1G3。在中位随访 48 个月内,35.5%的患者死于转移性 UCB。

结论

大约一半接受 RC 治疗且无新辅助化疗的临床 T1G3 UCB 患者被升级为肌层浸润性 UCB。这些数据支持当前治疗方案和分期工具基于临床决策的不足。因此,识别具有高疾病进展风险的临床 T1G3 疾病患者至关重要,因为这些患者可能从早期 RC 中获益。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验